AI Science Tracker

X, the Moonshot Factory

1 discovery from 2025

Discoveries

TeleProt-guided engineering yields a nuclease variant with improved neutral-pH biofilm degradation

A machine-learning-guided design and high-throughput screening campaign produced a Bacillus licheniformis NucB variant with 19-fold higher measured specific activity than wild type at pH 7. At 1 μM in a laboratory biofilm assay at neutral pH, the selected variant degraded 71% ± 2% of the biofilm versus 13% ± 3% for wild-type NucB.

Technology: TeleProt machine-learning-guided protein-library design framework; best-performing ML3 variant selected by model-based optimization with a deep neural network (MBO-DNN)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: A machine-learning-guided design and high-throughput screening campaign produced a Bacillus licheniformis NucB variant with 19-fold higher measured specific activity than wild type at pH 7.
  • Still unknown: The evidence is from enzyme and in-vitro B. licheniformis biofilm assays; it does not show wound healing, animal efficacy or clinical benefit. At the 1 μM dose, the paper reports the stated biofilm comparison; conditions and estimates are study-specific. This is engineering of a known nuclease, not discovery of a naturally new enzyme or organismal mechanism.
  • AI role: TeleProt combined sequence-evolutionary information with experimental genotype–phenotype data to propose diverse NucB variants for high-throughput microfluidic activity screening. The selected ML-guided variant was then purified and assessed in a lower-throughput nuclease assay and a neutral-pH biofilm degradation assay.

Evidence sources: https://doi.org/10.1016/j.cels.2025.101236

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 45 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.